REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot1362Original ArticleTop drugs of the Russian pharmaceutical market in 2017ArticleEditorialnoemail@neicon.ru1512201813S11415618032022Copyright © 2018,2018Every year Remedium publishes the traditional top 30 drug groups rating by sales in terms of value in 2017 (Table 1). Since the ATC classification is not the only classification system, the top drug groups ranking according to the EphMRA classification (European Association for Pharmaceutical Market Research, Table2) is presented for convenience.EphMRAIQVIARompharm companytop drugsVEDEphMRAARVIWHOATC classification systemMexidolvitaminsпрепараты - лидерыАТХ-классификацияВОЗЭликвисОРВИФентанилМексидолЖНВЛП1.Гиляров М.Ю., Константинова Е.В. Применение апиксабана в клинической практике. Эффективная фармакотерапия, 2015, 44: 6-12.2.Гиляров М.Ю., Константинова Е.В. Пероральные антикоагулянты в лечении венозных тромбоэмболических осложнений: фокус на апиксабан. Медицинский совет, 2017, 7: 56-72.3.Eliquis Nipping At The Heels of NOAC Market Leader Xarelto http://wwwcardiobrief.org/2016/10/20/eliquis-nipping-at-the-heals-of-noac-market-leader-xarelto/4.Инструкция по медицинскому применению лекарственного препарата Эликвис® от 20.02.2018.5.Pfizer. Executive summary October data point. 2017.6.Granger CB et al, Apixaban versus Warfarin in Patientswith Atrial Fibrillation. N Engl J Med, 2011, 365: 981-992.7.Connolly SJ et al. N Engl J Med, 2011, 364: 806-817.8.Введенская Е.С. О формировании современного понимания паллиативной помощи. Проблемы социальной гигиены, здравоохранения и истории медицины, 2013, 3.9.Абузарова Г.Р., Обухова О.А., Кашия Ш.Р. Использование наркотических анальгетиков в терапии хронического болевого синдрома онкологических больных. Онкогинекология, 2016, 1: 53-61.10.Моисеев С.В. Фентанил в виде трансдермальной терапевтической системы в лечении хронической боли. Паллиативная медицина и реабилитация, 2016, 2: 34-39.11.Зотов П.Б., Ральченко С.А., Хисматуллина А.Б., Мойсиев А.А. Некоторые особенности системной фармакотерапии хронической боли при первичном назначении трансдермальной терапевтической системы фентанила (Фендивия). Тюменский медицинский журнал, 2014, 16 (4): 49-50.12.Caraceni A et al. Guidelines of the European Association for Palliative Care (EAPC). Lancet Oncol, 2012, 13: 58-68.13.Инструкция по медицинскому применению ТТС Фендивия™.14.Tkssinari D, Sartori S, Tkmburini E. Adverse Effects of Transdermal Opiates Treating ModerateSevere Cancer Pain in Comparison to Long-Acting Morphine: A Meta-Analysis and Systematic Review of the Literature. J of Palliative Medicine, 2008, 11 (3): 492-501.15.Butler SF et al. Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J, 2006, Feb 2, 3: 5.16.Yang et al. REefsefaircchacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta Journal of Experimental & Clinical Cancer Research 2010, 29:67.17.Clark AJ, et al. Curr Med Res Opin, 2004, 20: 1419-29.18.Федеральный закон от 31.12.2014 № 501-ФЗ «О внесении изменений в Федеральный закон «О наркотических средствах и психотропных веществах». Статья 1, пункт 5.19.Пчелинцев М.В. Клинико-фармакологические особенности и преимущества трансдермального применения фентанила при сильной хронической боли. Лечащий Врач, 2016, 5.20.Стаховская Л.В. с соавт. Журнал неврологии и психиатрии, 2017, 117: 3(2): 55-65.21.Мексидол®: препарат выбора №1. Ремедиум, 2016, 3: 23.22.Мексидол® - первый лауреат премии «Молекула жизни». Фармацевтический вестник, 2016, декабрь, 40(869).23.Рейтинг наиболее влиятельных субъектов российского фармрынка в 2017 году. Часть 1. Фармацевтический вестник, 2018, февраль, 5.24.Янишевский С.Н. с соавт. Журнал неврологии и психиатрии, 2017, 12 (вып. 2): 78-86.25.Воронина ТА. Журнал неврологии и психиатрии, 2012, 2: 86-90.26.Смирнова И.Н. с соавт. Клиническая фармакология, 2006, 1: 33-36.27.Сайт группы компаний Rompharm Company http://www.rompharma.ru. Дата обращения: 05.04.2018.28.Инструкция по применению препарата Румалон.29.Сайт препарата Румалон. http://rumalon.ru Дата обращения: 05.04.2018.30.Rejholec V, Kralova M. Langzeitbehandlung der Coxarthrose mit Rumalon®. Akt Rheumatol, 1984, 9: 139-148. doi: 10.1055/s-2008-1048133.31.Алексеева Л.И., Кашеварова Н.Г, Таскина Е.А. и др. Эффективность и безопасность диацереина у пациентов с остеоартритом коленных суставов. Современная ревматология, 2017, 11(3): 50-57.32.Инструкция по применению препарата Диафлекс Ромфарм.33.Составляющие успеха - стабильность и нацеленность на результат. Интервью с ТЛ. Шиковым. 2017. №3. Ссылка: https://pharmvestnik.ru. Дата обращения: 05.04.2018.34.Инструкция по применению Гиалуром CS.35.Vvedenskaya ES. On the formation of a modern understanding of palliative care. Problems of social hygiene, health and history of medicine, 2013, 3.36.Abuzarova GR, Obukhova OA, Kashia Sh R. Use of narcotic analgesics in the treatment of chronic pain syndrome in cancer patients. Oncogynecology, 2016, 1: 53-61.37.Moiseev, S.V Fentanyl in the form of a transdermal therapeutic system for the treatment of chronic pain. Palliative Medicine and Rehabilitation, 2016, 2: 34-39.38.Zotov PB, Ralchenko SA, Khismatullina AB, Moisiev AA. Some features of systemic pharmacotherapy of chronic pain in the primary administration of the transdermal therapeutic system of fentanyl (Fendivia). Tyumen Medical Journal, 2014, 16 (4): 49-50.39.Caraceni A et al. Guidelines of the European Association for Palliative Care (EAPC). Lancet Oncol, 2012, 13: 58-68.40.Patient information leaflet for TTS Fendivia™.41.Tassinari D, Sartori S, Tkmburini E. Adverse Effects of Transdermal Opiates Treating ModerateSevere Cancer Pain in Comparison to Long-Acting Morphine: A Meta-Analysis and Systematic Review of the Literature. J of Palliative Medicine, 2008, 11 (3): 492-501.42.Butler SF et al. Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J, 2006, Feb 2, 3: 5.43.Yang et al. REefsefaircchacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating mod-eratesevere cancer pain in Chinese population: a systematic review and meta Journal of Experimental & Clinical Cancer Research 2010, 29:67.44.Clark AJ, et al. Curr Med Res Opin, 2004, 20: 1419-29.45.Federal Law No. 501-FZ On Amendments to the Federal Law On Narcotic Drugs and Psychotropic Substances of December 31, 2014. Article 1, paragraph 5.46.Stakhovskaya LV, et al. Journal of Neurology and Psychiatry 2017, 117: 3(2): 55-65.47.Mexidol®: the drug of choice number 1. Remedy, 2016, 3: 23.48.Mexidol® is the first laureate of the Life Molecule Award. Pharmaceutical Bulletin, 2016, December, 40 (869).49.Ranking of the most influential subjects of the Russian pharmaceutical market in 2017. Part 1. Pharmaceutical Bulletin, 2018, February, 5.50.Yanishevsky SN, et al. Journal of Neurology and Psychiatry, 2017, 12(issue 2): 78-86.51.Voronina TA. Journal of Neurology and Psychiatry, 2012, 2: 86-90.52.Smirnova IN, et al. Clinical Pharmacology, 2006, 1: 33-36.53.The web site of the Rompharm Company Group, http://www.rompharma.ru. Date of circulation: 04/05/2018.54.Patient Information Leaflet for Rumalon.55.The website of the drug Rumalon. http://rumalon.ru Date of circulation: 05/04/2018.56.Rejholec V, Kralova M. Langzeitbehandlung der Coxarthrose mit Rumalon®. Akt Rheumatol, 1984, 9: 139-148. doi: 10.1055 / s-2008-1048133.57.Alekseeva LI, Kashevarova NG, Taskina EA et al. Efficacy and safety of diacerein in patients with osteoarthritis of knee joints. Modern rheumatology, 2017, 11(3): 50-57.58.Patient Information Leaflet for Diaflex Rompharm.59.Stability and focus on results are components of success. Interview with TL. Shikov. 2017. №3. Link: https://pharmvest-nik.ru. Date of circulation: 04/05/2018.60.Patient Information Leaflet for Hyalurum CS.61.Kurkina AI, Klimenko KE. Modern aspects of pharmacotherapy and prevention of ARVI. Meditsinski Sovet, 2015, 11.62.The beginning of the 2017-2018 flu season and epidemiological surveillance over influenza in63.WHO European Region. WHO official website. Access mode: http://www.euro.who.int/64.en / health-topics / communicable-diseases / influenza / news / news / 2017/10 / start-of-regional-influenza-surveillance-for-the-20172018-season, free. Date of circulation: 19.03.2018.65.Patient Information Leaflet for Influnet®.66.Patient Information Leaflet for AnviMaks®.67.Official site of AnviMaks®. Access mode: http://www.anvimax.ru/, free68.The WHO website. Link: http://www.who.int /nutrition/ topics / ida/ ru/. Accessed date: 12.03.2018.69.Petrova EA. Effect of ionic and nonionic iron preparations on the immunity condition and lipid peroxidation indices in the oral cavity in pregnant women with iron deficiency anemia: Dissertation of PhD in medicine. Saransk, 2009.70.Kabasova KK. The use of Sorbifer® Durules® in the treatment of iron deficiency anemia. Vestnik Khirurgii Kazahstana, 2012, 1 (29).71.Patient Information Leaflet for Sorbifer® Durules®.72.Dvoretsky LI. Iron sulphate in the treatment of iron deficiency anemia: attitude endures. Terapevticheskiy Arkhiv, 2017, 10.73.Gordeeva OB, Botvineva VV. Contemporary view of iron deficiency anemia in children and treatment optimization. Medical Council, 2014, 6.74.Tyutyunnik VL et al. Iron deficiency in pregnant and breastfeeding women. Medical Council, 2017, 13.75.Novikova SV, et al. Optimization of management of pregnant women with high infectious risk. RMJ. Akusherstvo i Ginekologiya, 2015, 1.76.Gribkova IV. Pharmacoeconomic analysis of the use of oral iron preparations for the treatment and prevention of iron deficiency anemia in pregnant women. Akusherstvo i Ginekologiya, 2018, 3.77.Vykhristyuk YuV. Iron deficiency anemia in pregnant women: principles of treatment and prevention. Lechebnoe Delo, 2017,1.78.Antipenko EA, Gustov AV. Chronic cerebral ischemia: status update on the problem. Meditsinsky Sovet, 2016, 19: 38-43.79.Zakharov VV. Contemporary view of chronic circulatory insufficiency RMJ, 2014, 16: 1188.80.Damulin IV. Therapeutic potential and prospects for using the drug sermion (nicergoline) in neurological practice. Zhurnal Nevrologii I Psihiatrii, 2010, 12: 119-122.81.Ponomareva EV. The use of nicergoline (Sermion) in the complex therapy of late dementia in outpatient practice. Psychiatriya, 2017, 1: 49-59.82.Patient Information Leaflet for Sermion®.83.Kovalchuk VV, et al. Possible ways to normalize cognitive functions and psychoemotional state, as well as improve the quality of life in patients after stroke. Nervnye Bolezni, 2017, 1: 32-40.84.Pushkar D Yu, et al. The first pilot epidemiological study of the prevalence of erectile dysfunction in the Russian Federation. Urology, 2012, 6: 5-9.85.Gamidov SI, Ovchinnikov RI, Popova AYu. New aspects of the use of sildenafil for the treatment of erectile dysfunction. Medical Council, 2015, 11.86.Mazo EB, Dmitriev DG, Gamidov SI et al. Pharmacotherapy of erectile dysfunction. Breast cancer, 2001, 9: 1077-78.87.National Center for Biotechnology Information Search http://www.ncbi.nlm.nih.gov (accessed date: 01.11.2017).88.Lokshin KL. Comparative characteristics of sildenafil and other inhibitors of type 5 phosphodiesterase in the treatment of patients with erectile dysfunction (review of literature). BC, 2013, 18: 936-939.89.Lokshin KL Sildenafil in the treatment of patients with erectile dysfunction: summarizing and new possibilities of using the drug. RMJ, 2014, 11: 832-834.90.Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of Sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology, 2002, 60: 1227.91.Gamidov SI. Viagra: the past, the present and the future. RMJ, 2005, 2592.Kloner RA, Brown M, Prisant LM et al. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy Sildenafil Study Group. Am.J. Hypertens., 2001, 14 (1): 70-73.93.Mikhin NA. Varicose veins. Bulletin of medical Internet conferences, 2015, 5(5): 659.94.Gurfinkel YuI, Sasonko ML, Talov NA. Correction of blood microcirculation parameters and endothelial function in chronic venous insufficiency of lower extremities. Angiology and vascular surgery, 2017, 23 (2).95.Sonkin IN et al. The efficiency of Venarus in the treatment of patients with posttrombotic disease of lower extremities. Angiology and Vascular Surgery, 2014, 20.96.Zudin AM et al. Ultrasonic evaluation of changes in venous hemodynamics in patients with post-thrombotic disease with continuous reception of phlebotonics. Angiology and Vascular Surgery, 2014, 20.97.Patient Information Leaflet for Venarus.98.Official site for Venarus. Link: http://venarus.ru. Accessed date: 04.24.2018.99.Gudymovich VG. Phlebotrophic therapy with Venarus in patients with chronic venous insufficiency of lower extremities. Angiology and Vascular Surgery, 2013, 19(4).